Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10p -0.11% 91.90p 91.40p 91.90p 92.50p 91.25p 91.25p 1,276,203.00 16:35:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 2.4 1.5 0.3 367.6 760.01

Woodford Patient Capital (WPCT) Latest News (1)

More Woodford Patient Capital News
Woodford Patient Capital Takeover Rumours

Woodford Patient Capital (WPCT) Share Charts

1 Year Woodford Patient Capital Chart

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Woodford Patient Capital (WPCT) Discussions and Chat

Woodford Patient Capital Forums and Chat

Date Time Title Posts
20/1/201709:46Woodford Patient Capital Trust54.00
11/1/201719:19::: WOODFORD PATIENT CAPITAL TRUST :::990.00

Add a New Thread

Woodford Patient Capital (WPCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Woodford Patient Capital trades in real-time

Woodford Patient Capital (WPCT) Top Chat Posts

Woodford Patient Capital Daily Update: Woodford Patient Capital Trust is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker WPCT. The last closing price for Woodford Patient Capital was 92p.
Woodford Patient Capital Trust has a 4 week average price of 91.91p and a 12 week average price of 91.58p.
The 1 year high share price is 101.50p while the 1 year low share price is currently 80.50p.
There are currently 827,000,000 shares in issue and the average daily traded volume is 1,313,729 shares. The market capitalisation of Woodford Patient Capital Trust is £759,599,500.
jonwig: topvest - you could be right. I think the NAV will be less volatile than the market due to valuation rules. But the share price could well fall if the market does. Hence the discount widens. Lack of a dividend makes it less attractive, and I suppose there's still the background aim to issue more shares.
jonwig: Citywire has an article noting that WPCT is now at its cheapest, relative to NAV: Woodford Patient Capital Trust might be worth a look for anyone who didn’t join its £800 million record flotation in 2015. Neil Woodford’s trust has so far disappointed investors like me who leaped at the chance to back the star manager’s passion for early stage medical and technology stocks. After an early rally the stock slid back and at just under 90p is still a long way off its 100p launch price. However, the shares have rallied from a post-Brexit low of 81p, helped in part by the revival in healthcare and biotech prompted by the election of Donald Trump. Nevertheless, its share price gain has not fully reflected the advance in the net asset value of the underlying portfolio, the result being the discount has widened to 6%, close to the low reached after the EU referendum vote. It then goes on to analyse Z-scores of various trusts: Http://
netnut: Cut and pasted some points from the half year report. See the full report for finer details. ~ Netnut -- good operational progress among many holdings -- a number of companies have delivered strong returns -- negative sentiment towards health care sector impacted returns -- the Company's net asset value fell 10.8% to 86.81p -- two additional directors appointed to the Board
liquidkid: Wouldn't put it past him that since in the annual report he said something along the lines of "not doing another fund raising because no one could understand what the hell a C share issue is" He goes ahead and does a massive one on you because of the "market opportunity" in that the share price has decoupled so far away from the NAV.
dr biotech: I am pretty sure that he has all his money invested in either the WPCT or his equity funds. He is doing a live webcast as I type. NEIL WOODFORD says: Today 2:00 pm Kelvin (and others that have asked similar questions), The weakness of the WPCT share price and NAV since the start of 2016 has been the product of the pretty severe sell-off in shares across healthcare, biotech and early-stage quoted stocks, both here in the UK and in the US. Much of this, we believe to be driven by short-term positioning and rotational activity amongst the fund management community. We don’t believe that it is driven by a correction of over-valuation, nor by a deterioration in fundamentals. We remain very pleased with the underlying progress of the businesses in which we have invested in the trust. Indeed, in what has been a pretty short space of time since launch, our expectations for the underlying performance of many businesses in the portfolio have been exceeded. This is a long-term vehicle. We hope to deliver good performance in the short-term but believe we should be judged over the 3 to 5 year time scale we have talked about consistently since launch. Kind regards Neil
liquidkid: Don't want to have to put out another downer, but you just can't ignore that this is happening on a inexcusable level of regularity. And now for the Clanger of the week: Oxford-based e-Therapeutics' (ETX) most advanced drug flopped badly in a Phase IIb study for depression, beaten out on efficacy by an aging generic generiatric. Is The latest in a long lineup of companies to try a new strategy in combating depression and fail at it. Alkermes (ALKS) recently attempted its own pivotal study using a new study design that randomized nonresponders in the initial placebo group only to concede failure just weeks ago. This observation sums it up nicely Mach100 15 Feb'16 (ETX) Not an investor here but have seen a few presentations at Mayfair. They looked interesting at that time. Today's RNS seems weird to me. It seemed to be presented as good news when it is probably anything but. A massive drop first thing and any bottom feeders would have done well. I can't see given the wooliness of the RNS any great upside on this so I confess I am slightly bemused by the share price partial recovery since the opening. - The share price movement has all the hallmarks of Woofordunnit Meddling.
jonwig: If he's looking to raise new equity, his options are getting a bit limited. Ideally, he would like a substantial share price premium so that he can tuck the offer price between nav and share price His other option would be to to offer "C" shares at, say, 100p, and when these are fully invested have them convert on the basis of nav ratios. But this would fail to attract if the existing ords fell to a discount. His quoted holdings will carry a market valuation, but has he adjusted unquoteds at all?
liquidkid: Not trying to be disruptive here but what else has been going down on the unicorn farm this week? DRX -14% In the war on coal Drax is ISIS. Only James Bomb could get out of this position. Imperial Innov (IVO) -7% Dead in the market. no volume. none. a Deadweight RM2 -10% Ramps Up Stake as share price falls. Cap 171 mn UTW -15% UtilityWise - PowerStupid basket case. Make up the market, make up the numbers. Velocys VLS -13% IP Spin out - potential customers looking to harness the economics NetScientific -20% r&d Losses OWNS 45.3% NSCI -Ramps Up Stake as share price falls. and a nod to: Oxford Pharmascience (OXP)- straight line fall since June
bdog51: WPCT has nearly dropped all the way down to 100p IPO share price. 20% drop from the high point reached in August. I know it's meant for long term returns but I never expected such a large drop after such a promising start. Can someone explain why share price is down here after all the initial buying frenzy, large premium to NAV, Woodford popularity & reputation, etc? I'm a bit disappointed so far, hope the trust improves, the NAV doesn't seem to have varied much, it's the premium which has declined here. My holding here is showing a disappointing paper loss now. Agree with Minerve about Woodford Equity Fund - that's first class and the biggest part of my PF, for good reason. Great performance, highly recommended. Pity he's not having the same results with this "Patient" Trust !! I'm still holding WPCT anyway, suppose it could take a few years to get decent returns due to the extended revenue curve of start-ups? GLA
timbo003: Indeed, it looks like they are going to be issuing more shares to satisfy demand, which will no doubt put the brakes on the premium (see chairman's statement below) They will only issue at a premium, but what sort of premium, 2%, 5%, 7%, 10%? The board is very pleased to present the Woodford Patient Capital Trust's maiden interim results for the period ended 30 June 2015. The investment community's enthusiastic response to the launch of Woodford Patient Capital Trust surpassed our expectations. Since the initial public offering closed in April, Neil Woodford and his investment team have been busy deploying capital into a range of exciting young companies, together with a few more familiar mature businesses. As you will read in the Manager's Review, the team have already made great progress, with more than three-quarters of the £800m raised already deployed. The net asset value per share ended the period at 101.86p, so the portfolio has, thus far, recouped initial charges and provided a modestly positive return. The share price ended the period at 113.5p. The premium of 11.4%, in part, reflects the investment team's strong reputation and long-term track record but it has also arisen by virtue of the Company's entry into the FTSE 250 Index in mid-June, which will have resulted in demand from index trackers. In light of the current premium rating of the Company's shares, the Board intends to implement a tap issuance programme through its corporate broker, Winterflood Securities Limited, to satisfy excess demand in the secondary market. New shares issued under the tap issuance programme will only be issued at a premium to net asset value and will be accretive to existing shareholders. It is great to be off to a positive start, both in share price terms and in the form of portfolio progress. Whilst clearly it is early days, we are confident that this initial performance is indicative of the investment management team's ability to identify and invest in innovative, disruptive, typically science-based businesses at attractive valuations. We feel obliged to remind investors that as the name of the Company suggests, this is a long-term strategy. Its success should be judged over a number of years, not weeks or months. Nevertheless, the board is excited by the incredible potential that already exists in the portfolio, and we share the investment team's confidence in the future long-term growth prospects of the Company. Susan Searle Chairman 10 August 2015
Woodford Patient Capital share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170123 16:57:30